According to the latest report by IMARC Group “Artificial Insemination Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global artificial insemination market reached a value of US$ 1.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2027, exhibiting a CAGR of 8.6% during 2022-2027.
Artificial insemination refers to an assisted fertilization treatment wherein the sperm is artificially introduced into the cervix and uterus of a female. This procedure is employed through artificial insemination homologous (AIH), artificial insemination donor semen (AID), or intrauterine insemination (IUI). Artificial insemination is beneficial for infertility, old age, poor sperm quality, polycystic ovary syndrome (PCOS), and endometriosis. Other than this, artificial insemination is also adopted in animal breeding to conserve endangered species.
Request for a free sample copy of this report: https://www.imarcgroup.com/artificial-insemination-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The growing rate of infertility, changing lifestyles, and increasing awareness regarding the availability of alternative reproductive treatments are majorly driving the global artificial insemination market. The legalization of same-sex marriage by governments of various nations is further contributing to the market growth. Moreover, there has been an increase in the adoption of artificial insemination in the breeding of livestock animals as it is considered more hygienic, thereby preventing the spread of zoonotic diseases. This is also supported by the escalating demand for animal-based proteins.
Breakup by Type:
Breakup by Source Type:
Breakup by End Use:
- Hospitals and Clinics
- Fertility Centers
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Conceivex Inc.
- FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation)
- Genea Limited
- Genus plc
- Hamilton Thorne Inc.
- Hi-Tech Solutions
- Kitazato Corporation
- Pride Angel
- Rinovum Women’s Health LLC
- Rocket Medical plc
- TenderNeeds Fertility LLC
- Vitrolife AB.
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/artificial-insemination-market
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800